PubMed Health⌕ Search

Biomedical subjects

G Emödi

Publications and source records attributed to G Emödi.

13 recordsLinked to original sources
PubMed1977

Antiviral action of interferon in man: use of interferon in varicella - zoster infections in man.

The effect of human leukocyte interferon on varicella-zoster infections was compared in a placebo controlled study. Thirty-six patients were treated with interferon and 26 with placebo. In the interferon treated group the duration of pain was shortened, the development of crust formation was enhanced and the viral clearance from lesions was accelerated, compared with the control group.

Antiviral Agents↗
PubMed1976

Effect of human exogenous leukocyte interferon in cytomegalovirus infections.

Human leukocyte interferon was injected into nine patients with cytomegalovirus infections; four of these patients were congenitally infected, and five had acquired infections. In three patients viruria was completely inhibited. In five patients viral excretion in the urine was only transiently inhibited. Viremia was not significantly suppressed. The lymphocyte response to phytohemagglutinin was suppressed in two patients.

Adult↗
PubMed1975

Human interferon therapy for herpes zoster in adults.

Of 37 patients with herpes zoster 28 were treated with human exogenous interferon and 9 received only culture medium. The interferon was produced in leukocyte cultures and was given intramuscularly in one daily dose of 1 million units for 5-8 days. In the interferon-treated patients interferon was detectable in serum (peak level 1-5 hours after interferon injections) and in vesicle fluid, and in some patients also in urine samples. Anti-interferon antibodies were not found. Of the 28 interferon-treated patients 8 had a slight temperature increase and 4 showed a transient local reaction. In the interferon treated group of patients the duration of pain was shortened and the development of crust formation was enhanced compared with the control group.

Adolescent↗
PubMed1975

Circulating interferon in man after administration of exogenous human leukocyte interferon.

Interferon was measured at different intervals after the iv, sc, and im application of exogenous human leukocyte interferon to patients with various virus diseases or neoplasms. Interferon injected iv into patients had a half-life of about 15 minutes in the 1st hour and of about 90 minutes in the next 3 hours. Six hours after iv injection of 30 million U, no serum interferon was detectable. With a continuous iv infusion, a relatively high serum interferon level was reached. By the im administration of 1 million U interferon, a peak level of serum interferon (mean value 107 U/ml serum) occurred after 2 hours and was fairly stable for about 6 hours. Twenty-four hours after im application, a low level of serum interferon was still detectable. Similar results were found after sc interferon injections. In a patient with subacute sclerosing panencephalitis, no interferon was found in the cerebrospinal fluid at the time of the highest serum interferon level and 24 hours after two im interferon injections. Only minimal side reactions resulted from sc and im interferon injections. In one patient, a shock reaction occurred after iv application. For therapeutic trials, about 1 million U exogenous human interferon should be injected twice daily im or sc.

Encephalitis↗